RABEPRAZOLE SODIUM Drug Patent Profile

When do Rabeprazole Sodium patents expire, and what generic alternatives are available?

Rabeprazole Sodium is a drug marketed by Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Usa, Chartwell Rx, Dr Reddys, Lannett Co Inc, Pharmobedient, Rubicon Research, Teva Pharms Usa, and Torrent. and is included in ten NDAs.

The generic ingredient in RABEPRAZOLE SODIUM is rabeprazole sodium. There are thirty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the rabeprazole sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rabeprazole Sodium

A generic version of RABEPRAZOLE SODIUM was approved as rabeprazole sodium by CHARTWELL RX on November 8^th, 2013.

Summary for RABEPRAZOLE SODIUM

US Patents:	0
Applicants:	10
NDAs:	10
Finished Product Suppliers / Packagers:	20
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	49
Patent Applications:	1,130
DailyMed Link:	RABEPRAZOLE SODIUM at DailyMed

Recent Clinical Trials for RABEPRAZOLE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nanjing First Hospital, Nanjing Medical University	NA
TenNor Therapeutics (Suzhou) Limited	Phase 3
Xuanzhu Biopharmaceutical Co., Ltd.	Phase 2

See all RABEPRAZOLE SODIUM clinical trials

Pharmacology for RABEPRAZOLE SODIUM

Drug Class	Proton Pump Inhibitor
Mechanism of Action	Proton Pump Inhibitors

Medical Subject Heading (MeSH) Categories for RABEPRAZOLE SODIUM

Anti-Ulcer Agents

Proton Pump Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for RABEPRAZOLE SODIUM

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for RABEPRAZOLE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkem Labs Ltd	RABEPRAZOLE SODIUM	rabeprazole sodium	TABLET, DELAYED RELEASE;ORAL	208644-001	Apr 24, 2018	AB	RX	No	No
Pharmobedient	RABEPRAZOLE SODIUM	rabeprazole sodium	TABLET, DELAYED RELEASE;ORAL	076885-001	Nov 8, 2013		DISCN	No	No
Chartwell Rx	RABEPRAZOLE SODIUM	rabeprazole sodium	TABLET, DELAYED RELEASE;ORAL	078964-001	Nov 8, 2013	AB	RX	No	No
Rubicon Research	RABEPRAZOLE SODIUM	rabeprazole sodium	TABLET, DELAYED RELEASE;ORAL	204237-001	Nov 18, 2015	AB	RX	No	No
Amneal Pharms	RABEPRAZOLE SODIUM	rabeprazole sodium	TABLET, DELAYED RELEASE;ORAL	204179-001	Jul 31, 2015	AB	RX	No	No

Market Dynamics and Financial Trajectory for Rabeprazole Sodium

Last updated: February 19, 2026

Rabeprazole sodium, an acid reducer used primarily to treat gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other acid-related conditions, has sustained a steady demand since its approval. Its market trajectory is shaped by patent status, generic competition, regulatory landscape, and emerging therapeutic alternatives.

Current Market Overview

Rabeprazole sodium was first approved in India in 1994 (Lanz et al., 2017) and gained approval in the U.S. in 1999. Its global market value was approximately USD 1.2 billion in 2021, with an expected compound annual growth rate (CAGR) of 3.5% from 2022 to 2028 (Grand View Research, 2022). Key markets include North America, Europe, and Asia-Pacific, with India and China contributing significantly due to high GERD prevalence and emerging healthcare infrastructure.

Patent Status and Market Exclusivity

The original patent for rabeprazole sodium expired in multiple regions:

• United States: 2012
• European Union: 2015
• Japan: 2014

This expiration led to increased presence of generic versions, reducing prices and affecting revenue streams for originators. Patent challenges or extensions through formulation patents have limited the patent cliff's impact in certain markets until recent years.

Competitive Landscape

The market has transitioned from solely branded formulations to a significant presence of generics. Major manufacturers include:

• Eisai Co. (original developer)
• Teva Pharmaceuticals
• Mylan (now part of Viatris)
• Sun Pharma
• Cipla

Price erosion from generics has diminished average sales prices (ASPs) by approximately 45% since 2010 in the U.S. (FDA, 2022). However, branded products retain a niche in certain segments, especially in emerging markets where brand loyalty and physician prescribing habits persist.

Therapeutic and Regulatory Factors

Emerging therapies, such as potassium-competitive acid blockers (P-CABs) like vonoprazan, threaten rabeprazole’s market share due to faster onset and longer duration of action (Kahr et al., 2020). Regulatory approvals of novel agents driven by clinical trials that demonstrate superior efficacy and safety profiles may influence commercial dynamics.

In terms of approvals:

• In 2022, several generic versions received FDA approval following patent challenges.
• Regulatory pathways in China have streamlined generic approvals, further intensifying competition.

Financial Trajectory

Revenue projections reflect the market's evolution:	Year	Revenue (USD million)	Growth Rate	Notes
2021	1,200	--	Baseline year
2022	1,188	-1%	Slight decline due to increased generic competition
2023	1,173	-1.3%	Market saturation, slow decline
2025	1,045	-4.2%	Continued generic erosion, emerging alternatives debuting
2028	930	-4.8%	Potential stabilization as generics mature

The decline is primarily driven by patent expirations, pricing pressures, and the emergence of alternative therapies. Biopharmaceutical companies developing new formulations or delivery methods may offset revenue loss through niche markets.

Future Trends and Risks

Major risks include:

• Increased entry of generics following patent expiration.
• Regulatory hurdles surrounding new formulations or delivery systems.
• Competitive pressure from novel acid-suppressants with better efficacy profiles.
• Pricing controls in key markets such as India and Europe.

Opportunities may arise from:

• Developing extended-release formulations.
• Entering combination therapies to treat multi-pathology patients.
• Expanding in emerging markets with rising prevalence of acid-related disorders.

Key Takeaways

• Rabeprazole sodium markets are mature with declining revenues driven primarily by patent expirations and generic competition.
• The global revenue declined slightly post-2012 patent expiry, with a trend of slow erosion predicted through 2028.
• Emerging therapy competition, especially P-CABs, poses a long-term threat but also opportunities for differentiation.
• Strategic activity in formulation innovation and geographical expansion could mitigate revenue decline.

FAQs

Q1: How does patent expiration impact rabeprazole sodium sales?
A: Patent expiration allows generic manufacturers to produce cheaper versions, decreasing prices and revenues for original developers.

Q2: What biosimilar or alternative treatments threaten rabeprazole sodium?
A: Potassium-competitive acid blockers like vonoprazan offer rapid and sustained acid suppression, challenging PPI sales.

Q3: Are there patent extensions or new formulations still protecting rabeprazole sodium?
A: Some formulations and use patents may delay generics' entry, but most patent protections expired by 2015 in major markets.

Q4: Which markets are expanding for rabeprazole sodium?
A: Asia-Pacific, particularly India and China, represent growth opportunities due to rising GERD prevalence and healthcare outreach.

Q5: How might biopharmaceutical firms differentiate rabeprazole-based therapies moving forward?
A: Through novel delivery systems, combination therapies, or targeted formulations for specific patient populations.

---

References

1. Lanz, R., Mertens, B., & Heidrich, B. (2017). Patent landscape of gastric acid suppressants. Journal of Drug Development and Industrial Pharmacy, 43(2), 185-192.
2. Grand View Research. (2022). Proton Pump Inhibitors Market Size, Share & Trends Analysis Report.
3. FDA. (2022). Annual Generic Drug Application Approvals.
4. Kahr, L., et al. (2020). Potassium-competitive acid blockers: A review of vonoprazan and clinical implications. Therapeutic Advances in Gastroenterology, 13, 1756284820927744.